Shares of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) have earned an average rating of “Buy” from the six research firms that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, four have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $3.42.

A number of equities research analysts have recently weighed in on AVEO shares. Seaport Global Securities started coverage on shares of AVEO Pharmaceuticals in a research note on Friday. They issued a “buy” rating on the stock. FBR & Co restated a “buy” rating and issued a $3.00 price target on shares of AVEO Pharmaceuticals in a research note on Friday, June 30th. Piper Jaffray Companies set a $2.00 target price on shares of AVEO Pharmaceuticals and gave the stock a “buy” rating in a research report on Saturday, June 24th. Zacks Investment Research upgraded shares of AVEO Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.75 target price on the stock in a research report on Monday, July 24th. Finally, ValuEngine upgraded shares of AVEO Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 24th.

A number of large investors have recently bought and sold shares of AVEO. Sabby Management LLC acquired a new stake in AVEO Pharmaceuticals during the 1st quarter worth approximately $513,000. Perceptive Advisors LLC boosted its position in AVEO Pharmaceuticals by 64.3% during the 1st quarter. Perceptive Advisors LLC now owns 5,108,808 shares of the biopharmaceutical company’s stock worth $3,014,000 after buying an additional 2,000,000 shares during the period. Paloma Partners Management Co acquired a new stake in AVEO Pharmaceuticals during the 1st quarter worth approximately $184,000. UBS Oconnor LLC acquired a new stake in AVEO Pharmaceuticals during the 1st quarter worth approximately $291,000. Finally, Clear Harbor Asset Management LLC acquired a new stake in AVEO Pharmaceuticals during the 2nd quarter worth approximately $289,000. Institutional investors and hedge funds own 53.76% of the company’s stock.

AVEO Pharmaceuticals (NASDAQ:AVEO) traded down 1.4193% during midday trading on Friday, hitting $3.7855. 1,450,746 shares of the company were exchanged. The firm’s 50-day moving average price is $3.61 and its 200-day moving average price is $1.93. AVEO Pharmaceuticals has a one year low of $0.50 and a one year high of $4.24. The stock’s market capitalization is $447.85 million.

TRADEMARK VIOLATION NOTICE: This article was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international copyright law. The legal version of this article can be read at https://www.thecerbatgem.com/2017/10/09/brokerages-set-aveo-pharmaceuticals-inc-aveo-pt-at-3-42.html.

AVEO Pharmaceuticals Company Profile

AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.

Receive News & Stock Ratings for AVEO Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.